Appendix 2

Peer Reviewer Relationships With Industry and Others—ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly

Peer ReviewerRepresentationConsultantSpeaker's BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Emaad M. Abdel-RahmanOfficial Reviewer—American Society of NephrologyNoneNoneNoneNoneNoneNone
John BisognanoOfficial Reviewer—ACCF Board of GovernorsNoneNoneNoneNoneNoneNone
Ellen D. BurgessOfficial Reviewer—American Society of Nephrology
  • Bristol-Myers Squibb

  • Schering-Plough

  • Boehringer Ingelheim

  • Bristol-Myers Squibb*

  • Merck Frosst*

  • Novartis Pharmaceuticals

  • Sanofi-aventis*

  • Schering-Plough

None
  • Steering Committee for trial that is now “dead” —Bayer

NoneNone
Richard Cannon, IIIOfficial Reviewer—National Heart, Lung and Blood InstituteNoneNoneNoneNoneNoneNone
William CushmanOfficial Reviewer—American Heart Association and American Society of Preventive Cardiology
  • Bristol-Myers Squibb

  • Novartis Pharmaceuticals*

  • Sanofi-aventis

  • Takeda Pharmaceuticals

  • Theravance

NoneNone
  • NHLBI*

  • Novartis Pharmaceuticals

NoneNone
Richard M. DubinskyOfficial Reviewer—American Academy of Neurology
  • Allergan Pharmaceuticals, physician training

  • Allergan Pharmaceuticals

None
  • Site investigator for the following through subcontracts with the University of Rochester and Massachusetts General Hospital:

    • Allergan Pharmaceuticals

    • Merz Pharmaceuticals

    • NIH

  • American Academy of Neurology: Chair, Practice Improvement Subcommittee; Member, Practice Committee

  • Outgoing member, Huntington's Study Group Executive Committee

  • Defense deposition testimony, stroke in a young person 2008

  • Defense deposition and trial testimony, alleged traumatic brain injury 2009

Victor FerrariOfficial Reviewer—ACCF Task Force on Clinical Expert Consensus DocumentsNoneNoneNoneNoneNoneNone
Lawrence FineOfficial Reviewer—National Heart, Lung and Blood InstituteNoneNoneNoneNoneNoneNone
Sverre KjeldsenOfficial Reviewer—European Society of HypertensionNone
  • AstraZeneca LP

  • Boehringer Ingelheim

  • Novartis Pharmaceuticals

  • Sanofi-aventis

  • Takeda Pharmaceuticals

None
  • Norwegian Government

NoneNone
Robert PalmerOfficial Reviewer—American Geriatrics SocietyNoneNoneNoneNoneNoneNone
Robert A. PhillipsOfficial Reviewer—American Society of HypertensionNoneNoneNone
  • Monarch Pharmaceuticals*

NoneNone
Joseph RedonOfficial Reviewer—European Society of HypertensionNone
  • Boehringer Ingelheim

  • Merck Shark & Dohme

  • Novartis Pharmaceuticals

  • Pfizer

NoneNoneNoneNone
Elijah SaundersOfficial Reviewer—Association of Black Cardiologists
  • Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership

  • Forest

  • Novartis Pharmaceuticals

  • Pfizer

  • Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership

  • Forest Laboratories

  • Novartis Pharmaceuticals

  • Pfizer

None
  • Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership

  • Forest Laboratories

  • Novartis Pharmaceuticals

  • Pfizer

NoneNone
Pushpendra SharmaOfficial Reviewer—American Geriatrics SocietyNoneNoneNoneNoneNoneNone
Vincenza SnowOfficial Reviewer—American College of PhysiciansNoneNoneNone
  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Centers for Disease Control and Prevention

  • Merck Vaccines

  • Novo Nordisk

  • Sanofi Pasteur

  • Wyeth Pharmaceuticals

NoneNone
Sandra J. TalerOfficial Reviewer—American Society of HypertensionNoneNoneNoneNoneNoneNone
Carole WarnesOfficial Reviewer—ACCF Board of TrusteesNoneNoneNoneNoneNoneNone
Paul WheltonOfficial Reviewer—American Heart AssociationNoneNoneNoneNoneNoneNone
Jackson WrightOfficial Reviewer—Association of Black Cardiologists
  • Daiichi Sankyo

  • Novartis Pharmaceuticals

  • Sanofi-aventis

  • Take Care Health Systems

  • Wyeth Pharmaceuticals

NoneNone
  • CVRx

NoneNone
Nathan WongOfficial Reviewer—American Society of Preventive CardiologyNoneNoneNoneNoneNoneNone
Daniel FormanContent Reviewer—GeriatricNoneNoneNoneNoneNoneNone
Stanley FranklinContent Reviewer—HypertensionNoneNoneNoneNoneNoneNone
Andrew P. MillerContent Reviewer—HypertensionNone
  • AstraZeneca LP

  • Boehringer Ingelheim

  • Pfizer

None
  • Novartis

  • John A. Hartford Foundation

None
Nanette WengerContent Reviewer—Geriatrics
  • Abbott Laboratories

  • AstraZeneca LP

  • Boston Scientific

  • Genzyme

  • Gilead Sciences*

  • Medtronic

  • Merck

  • Pfizer

  • Schering-Plough*

NoneNone
  • Abbott Laboratories*

  • Eli Lilly*

  • Gilead Sciences*

  • Merck*

  • NHLBI*

  • Pfizer*

  • Sanofi-aventis*

NoneNone

This table represents the relevant relationships with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. ACCF indicates American College of Cardiology Foundation; NIH, National Institutes of Health; and NHLBI, National Heart, Lung, and Blood Institute.

  • * Significant relationship.